文献速递主动脉外科

开胸腹主动脉瘤修复后肋间或内脏动脉补片动脉瘤的腔内修复

Endovascular repair of intercostal and visceral aortic patch aneurysms following open thoracoabdominal aortic aneurysm repair.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-04-30

本研究回顾8个学术中心2011—2019年连续接受开窗分支腔内修复(F-BEVAR)治疗开胸腹主动脉瘤开放修复后肋间或内脏动脉补片动脉瘤的患者29例。技术成功率100%,无30天/院内死亡,主要不良事件17%,2年生存率96%,但再干预需求较高。

要点

  • F-BEVAR治疗开放TAAA修复后补片动脉瘤技术成功率100%且无围术期死亡。
  • 主要不良事件发生率17%,包括失血>1L、急性肾损伤、呼吸衰竭及短暂性轻截瘫。
  • 2年再干预免除率仅61%,需重视术后随访监测。

核心结论

  • 对于开胸腹主动脉瘤开放修复后出现内脏或肋间动脉补片动脉瘤的患者,F-BEVAR可作为再次开放手术的替代方案。
  • 本系列显示无死亡且主要不良事件发生率低,但再干预需求显著。

研究设计与样本

  • 回顾性多中心队列研究,纳入8个学术中心2011—2019年连续接受F-BEVAR治疗的29例患者。
  • 所有患者至少有一支靶血管需通过开窗或定向分支纳入。
  • 中位年龄70岁(四分位距63—74岁),7例(24%)有结缔组织病。

主要发现

  • 技术成功率为100%。
  • 无30天/院内死亡。
  • 主要不良事件发生于5例(17%),包括估计失血量>1 L 3例(10%)、急性肾损伤和呼吸衰竭各2例(7%)、短暂性轻截瘫1例(3%)。
  • 中位随访14个月(四分位距7—37个月)。
  • 2年时一期和二期通畅率、靶动脉不稳定免除率、再干预免除率和患者生存率分别为95%、100%、83%、61%和96%。

临床怎么用

  • 对于开放TAAA修复后补片动脉瘤的高危患者,F-BEVAR可考虑作为再次开放手术的替代。
  • 术后需密切随访,因2年再干预免除率仅61%。

局限性

  • 回顾性设计,样本量小(29例),随访时间有限(中位14个月)。
  • 仅纳入8个学术中心连续病例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reoperative open surgical repair (OSR) of thoracoabdominal aortic aneurysms (TAAAs) is associated with high morbidity and mortality. The aim of this study was to analyze outcomes of fenestrated-branched endovascular aneurysm repair (F-BEVAR) for the treatment of intercostal or visceral aortic patch aneurysms after OSR of TAAAs. METHODS: We reviewed the clinical data and outcomes of consecutive patients treated at 8 academic centers by F-BEVAR for visceral and intercostal aortic patch aneurysms after OSR of TAAAs (2011-2019). All patients had involvement of at least one target vessel requiring incorporation by a fenestration or directional branch. End points were technical success, 30-day and/in-hospital mortality, major adverse events, patient survival, target vessel patency/instability, and freedom from reintervention. RESULTS: There were 29 patients with a median age of 70 (interquartile range, 63-74) years. Seven patients (24%) had connective tissue disorders. Technical success was 100%. There were no 30-day/in-hospital mortalities. Major adverse events occurred in 5 patients (17%), including estimated blood loss >1 L in 3 patients (10%), acute kidney injury and respiratory failure in 2 patients (7%) each, and transient paraparesis in 1 patient (3%). Median follow-up was 14 (interquartile range, 7-37) months. At 2 years, primary and secondary patency, freedom from target artery instability, freedom from reintervention, and patient survival were 95%, 100%, 83%, 61%, and 96%, respectively. CONCLUSIONS: F-BEVAR could be considered as an alternative to reoperative OSR in patients with visceral or intercostal aortic patch aneurysms. This series showed no mortality and a low rate of major adverse events, but a significant need for reintervention.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Endovascular repair of intercostal and visceral aortic patch aneurysms following open thoracoabdominal aortic aneurysm repair. J Thorac Cardiovasc Surg. 2021. PMID: 34030882. doi:10.1016/j.jtcvs.2021.04.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。